Tempest Therapeutics Reports Critical Q1 Loss, Low Cash, Despite Strong Clinical Data
TPST sits 41% above its 52-week low of $1.5.
Summary
Tempest Therapeutics reported a significant net loss of $27.7 million for Q1 2026, reducing cash to $1.8 million, highlighting severe financial distress despite announcing positive clinical data for its lead CAR-T therapy, TPST-2003.
Key Events · Earnings and Guidance · TPST
-
Critical Cash Position
Cash and cash equivalents plummeted to $1.8 million as of March 31, 2026, down from $7.7 million at year-end 2025.
-
Significant Net Loss
Reported a net loss of $27.7 million for Q1 2026, a substantial increase from $10.9 million in Q1 2025.
-
Positive Clinical Data for TPST-2003
Announced a 100% complete response (CR) rate among 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 across two ongoing clinical trials, with a favorable safety profile.
-
Manufacturing Partnership Secured
Selected Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC) as the lead manufacturing partner for TPST-2003, supporting plans to initiate a potentially registrational study later this year.
Analysis · TPST · Life Sciences
The company's Q1 2026 financial results reveal a critical cash position, with only $1.8 million remaining and a net loss of $27.7 million for the quarter, which is nearly its entire market capitalization. This severe cash burn raises immediate concerns about the company's ability to continue operations, as also indicated by the 'going concern' language in its forward-looking statements. While the positive interim clinical data for TPST-2003 (100% complete response rate) is a significant scientific achievement and offers a potential path to value, the company faces an urgent need for substantial capital to fund its programs and address its liquidity crisis.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.9% of the 303 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.